Astrazeneca (AZN) Change in Working Capital (2009 - 2012)

Astrazeneca's Change in Working Capital history runs 4 years deep, the most recent figure standing at $312.0 million for Q4 2012.

• In Q4 2012, Change in Working Capital rose 85.71% year-over-year to $312.0 million; the TTM figure through Dec 2012 stood at $616.0 million (up 155.6% YoY), while the FY2012 annual figure was $312.0 million, up 85.71% from the prior year.
• Change in Working Capital was $312.0 million for Q4 2012 at Astrazeneca, up from $168.0 million in the prior quarter.
• In the past five years, Change in Working Capital ranged from a high of $312.0 million in Q4 2012 to a low of -$63.0 million in Q1 2009.
• Historically, Change in Working Capital has averaged $110.6 million across 4 years, with a median of $145.0 million in 2010.
• The sharpest annual moves came in 2010 and 2011: Change in Working Capital surged 1711.11% in 2010, then rose 15.86% in 2011.
• A 4-year view of Change in Working Capital shows it stood at -$9.0 million in 2009, then soared by 1711.11% to $145.0 million in 2010, then advanced by 15.86% to $168.0 million in 2011, then surged by 85.71% to $312.0 million in 2012.
• The last three Change in Working Capital figures came in at $312.0 million (Q4 2012), $168.0 million (Q4 2011), and $145.0 million (Q4 2010), per Business Quant data.